Open AccessAngiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis
Author(s) -
Imad M. Tleyjeh,
Aref A. Bin Abdulhak,
Haytham Tlayjeh,
Mouaz H. AlMallah,
M. Rizwan Sohail,
Leslie Hassett,
Jolanta M. SillerMatula,
Tarek Kashour
Publication year - 2020
Publication title -
american journal of therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.349
H-Index - 62
eISSN - 1536-3686
pISSN - 1075-2765
DOI - 10.1097/mjt.0000000000001319
Subject(s) - medicine , odds ratio , meta analysis , confidence interval , angiotensin converting enzyme , angiotensin receptor blockers , disease , medline , angiotensin receptor , angiotensin ii , receptor , blood pressure , political science , law
SARS-CoV-2 infects its target cells via angiotensin converting enzyme 2 receptor, a membrane-bound protein found on the surface of many human cells. Treatment with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptors blockers (ARB) has been shown to increase angiotensin converting enzyme 2 expression by up to 5-fold.